Published in J Clin Invest on August 15, 1998
Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci (2011) 5.64
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest (2000) 5.07
Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab (2006) 3.35
A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest (2012) 2.98
Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol (2005) 2.58
A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol (2008) 2.17
Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med (2013) 1.99
The choroid plexus removes beta-amyloid from brain cerebrospinal fluid. Exp Biol Med (Maywood) (2005) 1.97
Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets (2009) 1.94
RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci U S A (2009) 1.74
Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain. J Neurochem (2010) 1.47
The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr Pharm Des (2008) 1.36
Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.32
RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis (2009) 1.31
Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor. Blood (2010) 1.30
Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med (2009) 1.25
RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells (2011) 1.15
Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance. Nat Neurosci (2015) 1.13
Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease. J Alzheimers Dis (2013) 1.07
CNS drug delivery: opioid peptides and the blood-brain barrier. AAPS J (2006) 1.02
Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol Neurodegener (2011) 0.99
Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer's disease. Int J Alzheimers Dis (2012) 0.96
Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease. Mol Neurobiol (2007) 0.92
Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. J Alzheimers Dis (2011) 0.91
Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. Future Neurol (2009) 0.87
High dietary advanced glycation end products are associated with poorer spatial learning and accelerated Aβ deposition in an Alzheimer mouse model. Aging Cell (2016) 0.87
Is RAGE still a therapeutic target for Alzheimer's disease? Future Med Chem (2012) 0.86
Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier. Cytotechnology (2010) 0.85
Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities. Pharmacol Ther (2012) 0.85
BIN1 is decreased in sporadic but not familial Alzheimer's disease or in aging. PLoS One (2013) 0.83
Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease. Acta Neuropathol (2009) 0.82
Lymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer's Disease? Neuron (2016) 0.81
In vivo Differential Brain Clearance and Catabolism of Monomeric and Oligomeric Alzheimer's Aβ protein. Front Aging Neurosci (2016) 0.80
Cilostazol strengthens barrier integrity in brain endothelial cells. Cell Mol Neurobiol (2012) 0.79
RAGE mediated intracellular Aβ uptake contributes to the breakdown of tight junction in retinal pigment epithelium. Oncotarget (2015) 0.78
Cellular cofactors for amyloid beta-peptide-induced cell stress. Moving from cell culture to in vivo. Am J Pathol (1999) 0.78
Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications. Age (Dordr) (2010) 0.77
Shedding of soluble platelet-derived growth factor receptor-β from human brain pericytes. Neurosci Lett (2015) 0.77
Decreased Plasma Aβ in Hyperlipidemic APPSL Transgenic Mice Is Associated with BBB Dysfunction. Front Neurosci (2016) 0.77
RAGE Expression and ROS Generation in Neurons: Differentiation versus Damage. Oxid Med Cell Longev (2016) 0.76
Pentosan polysulfate regulates scavenger receptor-mediated, but not fluid-phase, endocytosis in immortalized cerebral endothelial cells. Cell Mol Neurobiol (2000) 0.76
2016 ATVB Plenary Lecture: Receptor for Advanced Glycation Endproducts and Implications for the Pathogenesis an Treatment of Cardiometabolic Disorders: Spotlight on the Macrophage. Arterioscler Thromb Vasc Biol (2017) 0.75
Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin (2017) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A (1985) 16.10
Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell (1993) 10.15
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature (1992) 7.02
Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science (1992) 5.22
Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature (1996) 3.92
Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol (1997) 3.22
beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature (1996) 2.82
Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A (1996) 2.79
The pathogenesis of senile plaques. J Neuropathol Exp Neurol (1997) 2.49
An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature (1997) 2.42
A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J Immunol (1997) 2.15
Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem (1996) 1.96
Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A (1994) 1.85
Mathematical theory of complex ligand-binding systems of equilibrium: some methods for parameter fitting. Anal Biochem (1972) 1.84
Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier. Neurobiol Dis (1997) 1.83
TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Mol Med (1997) 1.65
A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol (1997) 1.64
Transmissible and non-transmissible amyloidoses: autocatalytic post-translational conversion of host precursor proteins to beta-pleated sheet configurations. J Neuroimmunol (1988) 1.63
Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci U S A (1996) 1.52
Blood-brain barrier transport of circulating Alzheimer's amyloid beta. Biochem Biophys Res Commun (1993) 1.48
Biology of A beta amyloid in Alzheimer's disease. Neurobiol Dis (1997) 1.45
Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J Clin Invest (1997) 1.37
Receptor-mediated peptide transport through the blood-brain barrier. Endocr Rev (1986) 1.35
Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J Neurochem (1997) 1.35
Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem (1998) 1.34
Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun (1994) 1.27
High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am J Pathol (1994) 1.24
Passage of human amyloid beta-protein 1-40 across the murine blood-brain barrier. Life Sci (1994) 1.21
Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Pharm Res (1995) 1.16
Surface binding and rates of internalization of 125I-insulin in adipocytes and IM-9 lymphocytes. J Biol Chem (1982) 1.10
Phenylarsine oxide inhibition of endocytosis: effects on asialofetuin internalization. Am J Physiol (1989) 1.03
Intra-arterial infusion of [125I]A beta 1-40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport (1996) 1.01
Ligand binding to macrophage scavenger receptor-A induces urokinase-type plasminogen activator expression by a protein kinase-dependent signaling pathway. J Biol Chem (1998) 1.00
The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease. J Biol Chem (1996) 0.99
Use of isolated brain capillaries and cultured endothelial cells to study the blood-brain barrier. Fed Proc (1984) 0.98
Two conformational states of amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. Neurosci Lett (1995) 0.97
Alzheimer's disease. Amyloid ox-tox transducers. Nature (1996) 0.90
Selective binding of soluble Abeta1-40 and Abeta1-42 to a subset of senile plaques. Am J Pathol (1996) 0.89
Can blood-brain barrier play a role in the development of cerebral amyloidosis and Alzheimer's disease pathology. Neurobiol Dis (1997) 0.86
Absorptive-mediated endocytosis of a dynorphin-like analgesic peptide, E-2078 into the blood-brain barrier. J Pharmacol Exp Ther (1989) 0.84
Identification and distribution of insulin receptors on cultured bovine brain microvessel endothelial cells: possible function in insulin processing in the blood-brain barrier. J Cell Physiol (1994) 0.84
Carrier-mediated transport of vasopressin across the blood-brain barrier of the mouse. J Neurosci Res (1987) 0.83
Multiple pathways for ligand internalization in rat hepatocytes. I: Effects of anoxia, phenylarsine oxide and monensin. J Cell Physiol (1991) 0.83
Blood-brain barrier: transport studies in isolated brain capillaries and in cultured brain endothelial cells. Adv Pharmacol (1991) 0.83
Expression of receptors for native and chemically modified low-density lipoproteins in brain microvessels. FEBS Lett (1997) 0.80
Delivering peptides to the central nervous system: dilemmas and strategies. Pharm Res (1991) 0.80
In vivo vascular damage, leukocyte activation and inflammatory response induced by beta-amyloid. J Submicrosc Cytol Pathol (1997) 0.78
Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science (2001) 15.54
Accessing genetic information with high-density DNA arrays. Science (1996) 13.89
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55
Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood (1998) 7.70
The Berkeley Drosophila Genome Project gene disruption project: Single P-element insertions mutating 25% of vital Drosophila genes. Genetics (1999) 7.56
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 6.70
Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 5.60
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med (1998) 5.54
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest (2001) 5.49
Top-down facilitation of visual recognition. Proc Natl Acad Sci U S A (2006) 5.38
Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science (1992) 5.22
Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med (1986) 5.17
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest (2000) 5.07
Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med (1982) 4.98
Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science (1990) 4.71
Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett (1992) 4.29
Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med (1998) 4.17
The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils. J Clin Invest (1972) 3.96
Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med (1990) 3.93
Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes (2001) 3.83
Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol (1993) 3.73
Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem (1994) 3.73
N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem (1999) 3.72
Functional dissection and sequence of yeast HAP1 activator. Cell (1989) 3.56
Outer membrane protein A of Escherichia coli contributes to invasion of brain microvascular endothelial cells. Infect Immun (1996) 3.53
The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta (2000) 3.33
Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol (1997) 3.22
Mycobacterium. Bacteriol Rev (1977) 3.20
Purification and properties of staphylococcal delta hemolysin. Infect Immun (1971) 3.19
Dexamethasone therapy for children with bacterial meningitis. Meningitis Study Group. Pediatrics (1995) 2.98
Anaerobic degradation of toluene by a denitrifying bacterium. Appl Environ Microbiol (1991) 2.98
Invasion of brain microvascular endothelial cells by group B streptococci. Infect Immun (1997) 2.97
Human optic nerve fiber count and optic disc size. Invest Ophthalmol Vis Sci (1992) 2.94
Escherichia coli invasion of brain microvascular endothelial cells in vitro and in vivo: molecular cloning and characterization of invasion gene ibe10. Infect Immun (1995) 2.91
Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab (2001) 2.91
RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun (2002) 2.88
Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A (1996) 2.79
Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med (1989) 2.69
Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett (1989) 2.69
Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol (1994) 2.66
The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J (1993) 2.66
Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem (1997) 2.66
Infection of Phaseolus vulgaris by bean golden mosaic virus: ultrastructural aspects. Virology (1978) 2.64
Structural studies of immunoglobulin G. Nature (1969) 2.63
Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res (1999) 2.59
Variations in the S-S bridges of immunoglobins G: interchain disulfide bridges of gamma G3 myeloma proteins. J Mol Biol (1968) 2.57
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol (1999) 2.56
Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem (1997) 2.53
Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med (1989) 2.52
A stop-codon mutation in the BRI gene associated with familial British dementia. Nature (1999) 2.46
Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest (2001) 2.45
Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med (2000) 2.44
Human amyloidosis, Alzheimer disease and related disorders. Lab Invest (1988) 2.44
An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature (1997) 2.42
Context, conflict, and resolution: a new conceptual framework for evaluating professionalism. Acad Med (2000) 2.39
Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol (2001) 2.38
Importance of bacterial growth phase in determining minimal bactericidal concentrations of penicillin and methicillin. Antimicrob Agents Chemother (1981) 2.35
Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol (2001) 2.33
The disulphide bonds of the heavy chain of rabbit immunoglobulin G. Biochem J (1970) 2.32
Retracted Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue. Nature (2000) 2.31
Alpha chain disease. Ann N Y Acad Sci (1971) 2.31
Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis (2005) 2.28
Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neurosci Lett (1988) 2.26
Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem (1988) 2.24
Staphylococcal sphingomyelinase (beta-hemolysin). Ann N Y Acad Sci (1974) 2.22
Binding characteristics of S fimbriated Escherichia coli to isolated brain microvascular endothelial cells. Am J Pathol (1994) 2.21
Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res (2007) 2.21
Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest (1996) 2.19
CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology (2006) 2.19
Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci U S A (1990) 2.18
In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease beta-protein. Biochem Biophys Res Commun (1986) 2.16
Structure-activity relationships of chemokines. J Leukoc Biol (1995) 2.15
A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J Immunol (1997) 2.15
A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci U S A (2000) 2.11